MAPK1 and cancer: Since the most common clinical resistance mechanism implies the reactivation of the RAF/MEK/ERK pathway by various mechanisms, the targeting of ERK itself has become an emerging novel therapy in MAPK kinase-driven cancers and ERK inhibitors are currently being tested in clinical trials.